Skip to main content
. 2013 Oct 11;8(1):136. doi: 10.1007/s11657-013-0136-1

Table 11.

Cost-effectiveness of alendronate (cost (£000)/QALY gained) in UK women with clinical risk factors according to age and T-score for femoral neck BMD [107]. A cost of less than £20–30,000/QALY gained is considered to be cost-effective

graphic file with name 11657_2013_136_Tab12_HTML.jpg

c.s. = cost-saving